Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt 1439.00
MRNA's Cash to Debt is ranked higher than
80% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. MRNA: 1439.00 )
MRNA' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 1439

F-Score: 3
Z-Score: -42.97
M-Score: -4.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) -51.39
MRNA's Operating margin (%) is ranked higher than
73% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. MRNA: -51.39 )
MRNA' s 10-Year Operating margin (%) Range
Min: -2259.18   Max: -2.56
Current: -51.39

-2259.18
-2.56
Net-margin (%) -382.84
MRNA's Net-margin (%) is ranked higher than
60% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. MRNA: -382.84 )
MRNA' s 10-Year Net-margin (%) Range
Min: -2269.84   Max: 2.56
Current: -382.84

-2269.84
2.56
ROA (%) -72.93
MRNA's ROA (%) is ranked higher than
56% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. MRNA: -72.93 )
MRNA' s 10-Year ROA (%) Range
Min: -450.79   Max: 1.06
Current: -72.93

-450.79
1.06
Revenue Growth (%) -55.90
MRNA's Revenue Growth (%) is ranked higher than
57% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. MRNA: -55.90 )
MRNA' s 10-Year Revenue Growth (%) Range
Min: -73   Max: 72
Current: -55.9

-73
72
EBITDA Growth (%) -81.80
MRNA's EBITDA Growth (%) is ranked higher than
50% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. MRNA: -81.80 )
MRNA' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 121.7
Current: -81.8

0
121.7
EPS Growth (%) -82.10
MRNA's EPS Growth (%) is ranked higher than
53% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. MRNA: -82.10 )
MRNA' s 10-Year EPS Growth (%) Range
Min: -82.1   Max: 101
Current: -82.1

-82.1
101
» MRNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MRNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -20.05
MRNA's EV-to-EBIT is ranked higher than
59% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MRNA: -20.05 )
MRNA' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -20.05

Current Ratio 2.17
MRNA's Current Ratio is ranked higher than
61% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. MRNA: 2.17 )
MRNA' s 10-Year Current Ratio Range
Min: 0.03   Max: 21.21
Current: 2.17

0.03
21.21
Quick Ratio 2.17
MRNA's Quick Ratio is ranked higher than
64% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. MRNA: 2.17 )
MRNA' s 10-Year Quick Ratio Range
Min: 0.03   Max: 21.07
Current: 2.17

0.03
21.07

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) -1342.37
MRNA's Forward Rate of Return (Yacktman) is ranked higher than
52% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. MRNA: -1342.37 )
MRNA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -1342.37

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Marina Biotech, Inc., formerly known as Nastech Pharmaceutical Company Inc., was incorporated in Delaware in 1983. The Company is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference ('RNAi') and blocking messenger RNA ('mRNA') translation. It has multiple proprietary technologies integrated into a nucleic acid-based drug discovery platform, with the capability to deliver novel nucleic acid-based therapeutics via systemic, local and oral administration to target a range of human diseases, based on the unique characteristics of the cells and organs involved in each disease. Its pipeline includes a clinical program in Familial Adenomatous Polyposis ('FAP') and preclinical programs in bladder cancer and myotonic dystrophy. In addition to its own, internally developed technologies, it has strategically in-licensed and further developed nucleic acid- and delivery-related technologies, forming an integrated drug discovery platform. It is employing its platform, through its own efforts and those of its partners, for the discovery of multiple nucleic acid-based therapeutics including siRNA, microRNA, and single stranded oligonucleotide-based drugs. It's competitors include Alnylam Pharmaceuticals, Benitec Biopharma, Dicerna Pharmaceuticals, miRagen Therapeutics, Mirna Therapeutics, Quark Pharmaceuticals, Regulus Therapeutics, Silence Therapeutics, and Tekmira Pharmaceuticals. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.
» More Articles for MRNA

Headlines

Articles On GuruFocus.com
x pie = y Jul 01 2011 
MDRNA Inc. Reports Operating Results (10-Q) Nov 15 2010 
MDRNA Inc. Reports Operating Results (10-Q) May 17 2010 
MDRNA Inc. Reports Operating Results (10-Q) Nov 12 2009 
MDRNA Inc. Reports Operating Results (10-Q) Jul 30 2009 
MDRNA Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
Marina Biotech Announces the Election of Donald A. Williams to Its Board of Directors Sep 16 2014
Marina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual... Sep 11 2014
Marina Biotech to Present Rare Disease Clinical Strategy at Upcoming Investor Conferences Sep 03 2014
MARINA BIOTECH, INC. Financials Aug 26 2014
Marina Biotech Regains Compliance With Exchange Act Reporting Obligations Aug 20 2014
MARINA BIOTECH, INC. Files SEC form 10-Q, Quarterly Report Aug 19 2014
MARINA BIOTECH, INC. Files SEC form 10-Q, Quarterly Report Aug 07 2014
MARINA BIOTECH, INC. Files SEC form 10-K, Annual Report Aug 05 2014
MARINA BIOTECH, INC. Files SEC form 10-K, Annual Report Jul 22 2014
Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic... Jun 12 2014
Marina Biotech Receives Decision to Grant Japanese Patent for Its SMARTICLES Nucleic Acid Delivery... Jun 05 2014
Marina Biotech to Present at the LD Micro Invitational 2014 May 28 2014
MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers May 19 2014
Marina Biotech Provides Organizational Update May 14 2014
MARINA BIOTECH, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial... May 13 2014
Marina Biotech Presents Clinical Data Demonstrating Delivery of Both Single and Double-Stranded... May 06 2014
Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based... Apr 02 2014
MARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered... Mar 11 2014
Marina Biotech to Use Its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for... Mar 11 2014
MARINA BIOTECH, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities Feb 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK